Integrative clinical sequencing in the management of refractory or relapsed cancer in youth

JAMA - Journal of the American Medical Association

Volumn 314, Issue 9, 2015, Pages 913-925

  Mody, Rajen J ^a,b   Wu, Yi Mi ^b,c   Lonigro, Robert J ^a,b   Cao, Xuhong ^a,b,c   Roychowdhury, Sameek ^d   Vats, Pankaj ^b   Frank, Kevin M ^a   Prensner, John R ^b,e   Asangani, Irfan ^b,c   Palanisamy, Nallasivam ^b   Dillman, Jonathan R ^c   Rabah, Raja M ^c   Kunju, Laxmi Priya ^c   Everett, Jessica ^c   Raymond, Victoria M ^c   Ning, Yu ^b   Su, Fengyun ^b   Wang, Rui ^b   Stoffel, Elena M ^c   Innis, Jeffrey W ^a   Roberts, J Scott ^a   Robertson, Patricia L ^a   Yanik, Gregory ^a   Chamdin, Aghiad ^f   Connelly, James A ^a   Choi, Sung ^a   Harris, Andrew C ^a   Kitko, Carrie ^a   Rao, Rama Jasty ^a   Levine, John E ^a   Castle, Valerie P ^a   Hutchinson, Raymond J ^a   Talpaz, Moshe ^a,d   Robinson, Dan R ^b,c   Chinnaiyan, Arul M ^a,b,c   more..

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; DNA; IMATINIB; RNA; RUXOLITINIB; SORAFENIB; TOFACITINIB; TRANSCRIPTOME;

ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER THERAPY; CANCER TISSUE; CASE STUDY; CHILD; CONTROLLED STUDY; EXOME; FAMILY; FEMALE; GENE SEQUENCE; GENETIC COUNSELING; GENETIC SCREENING; HEMATOLOGIC MALIGNANCY; HUMAN; INFANT; JUVENILE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PERSONALIZED MEDICINE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOLID TUMOR; YOUNG ADULT; CHROMOSOME ABERRATION; DNA SEQUENCE; FEASIBILITY STUDY; GENE FUSION; GENETICS; HEMATOLOGIC DISEASE; INCIDENTAL FINDING; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NEWBORN; PRESCHOOL CHILD; PROCEDURES; REMISSION; TUMOR RECURRENCE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; FAMILY; FEASIBILITY STUDIES; GENE FUSION; GENETIC COUNSELING; HEMATOLOGIC NEOPLASMS; HUMANS; INCIDENTAL FINDINGS; INFANT; INFANT, NEWBORN; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); REMISSION INDUCTION; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84940769044     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.10080     Document Type: Article

References (39)

1. Gaynon PS, Angiolillo AL, Carroll WL, et al Children's Oncology Group. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia. 2010;24(2):285-297.
2. Moroz V, Machin D, Faldum A, et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2011;47(4):561-571.
3. Thiele CJ, Cohn SL. Genetically InFormed therapies-a "GIFT" for children with cancer. Clin Cancer Res. 2012;18(10):2735-2739.
4. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29 (5):551-565.
5. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008; 26(14):2384-2389.
6. London WB, Castel V, Monclair T, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011;29(24):3286-3292.
7. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):153-166.
8. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11(10):685-696.
9. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitorand Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11): 1243-1246.
10. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: National Academies Press; 2011.
11. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
12. Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481(7381):329-334.
13. Wu G, Broniscer A, McEachron TA, et al St Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and nonbrainstem glioblastomas. Nat Genet. 2012;44(3):251-253.
14. WelchJS,WesterveltP,DingL,etal.Useof whole-genome sequencing to diagnose a cryptic fusion oncogene.JAMA. 2011;305(15):1577-1584.
15. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011;3(111):111ra121.
16. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565-574.
17. Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Nat Genet. 2013;45(12):1446-1451.
18. Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3(6):636-647.
19. O'Brien SG, Vieira SA, Connors S, et al. Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. Blood. 2002;99(9):3465-3467.
20. Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah E. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res. 2009;33(8):1144-1146.
21. Widemann BC, Kim A, Fox E, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.Clin Cancer Res. 2012;18(21):6011-6022.
22. Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PH. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol. 2000;24(7):937-946.
23. Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med.2013;19 (11):1469-1472.
24. Cui JJ, Tran-Dubé M, Shen H, et al Structure based drug design of crizotinib (pf-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET)kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011;54(18):6342-6363.
25. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.JClin Oncol. 2002;20(11):2672-2679.
26. Mosquera JM, Sboner A, Zhang L, et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer. 2013;52(6): 538-550.
27. Sumegi J, Streblow R, Frayer RW, et al. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer. 2010;49(3):224-236.
28. Bradford R, Crockard HA, Isaacson PG. Primary rhabdomyosarcoma of the central nervous system: case report.Neurosurgery. 1985;17(1):101-104.
29. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants.JClin Oncol. 2011;29(11):1408-1414.
30. Carbone M, Ferris LK, Baumann F, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012;10:179.
31. Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011;331(6016):435-439.
32. Janeway KA, Place AE, Kieran MW, Harris MH. Future of clinical genomics in pediatric oncology. J Clin Oncol. 2013;31(15):1893-1903.
33. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature.2013;499 (7457):214-218.
34. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484): 495-501.
35. Fernandez CV, Gao J, Strahlendorf C, et al. Providing research results to participants: attitudes and needs of adolescents and parents of children with cancer. J Clin Oncol. 2009;27(6):878-883.
36. Tabor HK, Brazg T, Crouch J, et al. Parent perspectives on pediatric genetic research and implications for genotype-driven research recruitment. J Empir Res Hum Res Ethics. 2011;6(4): 41-52.
37. Haga SB, O'Daniel JM, Tindall GM, Lipkus IR, Agans R. Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions. Genet Med. 2011;13(8):723-728.
38. Wilfond BS, Carpenter KJ. Incidental findings in pediatric research. J Law Med Ethics. 2008;36(2): 332-340.
39. Goltsov A, Langdon SP, Goltsov G, Harrison DJ, Bown J. Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations. Front Oncol.2014; 4:13.